公开(公告)号：HK1078566A1

公开(公告)日：2006-03-17

申请号：HK05110489

申请日：2005-11-21

Applicant: SERVIER LAB

Inventor： DASSONVILLE ALEXANDRA ,  BRETECHE ANNE ,  DUFLOS MURIEL ,  BAUT GUILLAUME LE ,  PFEIFFER BRUNO ,  RENARD PIERRE ,  LEVENS NIGEL ,  HUSSON-ROBERT BERNADETTE

IPC: C07C20060101 ,  A61K20060101 ,  A61K31/122 ,  A61K31/222 ,  A61K31/4402 ,  A61P20060101 ,  A61P3/10 ,  C07C45/00 ,  C07C45/28 ,  C07C46/00 ,  C07C46/10 ,  C07C50/28 ,  C07C50/30 ,  C07D20060101 ,  C07D213/50

Abstract: Compound of formula (I): wherein: R 1 and R 2 , which may be identical or different, each represents hydrogen, acyl or alkyl, Ar represents aryl or heteroaryl, A represents a group selected from: R 4 represents hydrogen or alkyl, R 5 represents hydrogen, alkyl, aryl or heteroaryl, R 3 represents aryl, heteroaryl, dicyclopropylmethyl or benzhydryl, or A-R 3 represents an optionally substituted naphthyl group, with the exclusion of 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-phenylethenyl)-1,4-benzoquinone, 2,5-dihydroxy-3-(4-methoxyphenyl)-6-(2-naphthyl)-1,4-benzoquinone and 2,5-dihydroxy-3-(2-naphthyl)-6-phenyl-1,4-benzoquinone. Medicinal products containing the same which are useful in the treatment of diseases associated with a deregulation of glycaemia.

公开(公告)号：DE60201296T2

公开(公告)日：2006-02-23

申请号：DE60201296

申请日：2002-06-17

Applicant: SERVIER LAB

Inventor： WIERZBICKI MICHEL ,  FOURQUEZ JEAN-MARIE ,  LEVENS NIGEL ,  HUSSON-ROBERT BERNADETTE ,  NOSJEAN OLIVIER ,  BOULANGER MICHELLE

IPC: C07D295/18 ,  A61K31/16 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/426 ,  A61K31/4453 ,  A61K31/5375 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  C07C237/14 ,  C07D205/04 ,  C07D207/18 ,  C07D207/20 ,  C07D209/02 ,  C07D209/52 ,  C07D277/04 ,  C07D277/22 ,  C07D295/185

Abstract: A compound of formula (I):wherein:represents an optionally substituted saturated carbon ring having from 4 to 8 ring members,R1 and R4, which may be identical or different, each represents hydrogen or acyl,R2 and R3, which may be identical or different, each represents hydrogen or alkyl,R5 and R6, which may be identical or different, each represents hydrogen or alkyl, or R5 and R6 together, with the nitrogen atom carrying them, form an optionally substituted nitrogen-containing heterocycle,stereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.Medicinal products containing the same which are useful for treatment of glucose intolerance or of disorders associated with hyperglycaemia.

公开(公告)号：FR2824825B1

公开(公告)日：2005-05-06

申请号：FR0106375

申请日：2001-05-15

Applicant: SERVIER LAB

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  BENOIST ALAIN ,  LEVENS NIGEL ,  NOSJEAN OLIVIER ,  HUSSON ROBERT BERNADETTE ,  BOULANGER MICHELLE

IPC: C07D295/10 ,  A61K31/40 ,  A61K31/426 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  C07D207/16 ,  C07D277/04 ,  C07D277/06 ,  C07D295/185 ,  C07K5/02 ,  C07D207/42

Abstract: Alpha amino acid derivatives (I), their optical isomers and addition salts, are new. Alpha amino acid derivatives of formula (I), their optical isomers and addition salts, are new: A = five-membered heterocycle, optionally substituted by a cyano group; Ak = 1-6C alkylene; X = single bond or phenylene; R1, R2, R4 = H or 1-6C alkyl; Y = NR4 or CH-NO2; R3 = NO2 or CN; and provided that: (i) when Y is CH-NO2, then R3 may further be 1-6C alkyl; and (ii) when A is unsubstituted, then Ak is propylene, X is a bond, Y is NH and R3 is NO2, are excluded.

公开(公告)号：MA27103A1

公开(公告)日：2004-12-20

申请号：MA27795

申请日：2004-07-21

Applicant: SERVIER LAB

Inventor： DASSONVILLE ALEXANDRA ,  BRETECHE ANNE ,  DUFLOS MURIEL ,  LE BAUT GUILLAUME ,  PFEIFFER BRUNO ,  RENARD PIERRE ,  LEVENS NIGEL ,  HUSSON-ROBERT BERNADETTE

IPC: A61K31/122 ,  A61K31/222 ,  A61K31/4402 ,  A61P3/10 ,  C07C45/00 ,  C07C45/28 ,  C07C46/00 ,  C07C46/10 ,  C07C50/28 ,  C07C50/30 ,  C07D213/50

Abstract: NOUVEAUX DERIVES DE 3-ARYL-2,5-DIHYDROXY-1,4-BENZOQUINONES, LEUR PROCEDE DE PREPARATION ET LES COMPOSITIONS PHARMACEUTIQUES QUI LES CONTIENNENT Composé de formule (I): dans laquelle : R1 et R2, identiques ou différents, représentent chacun un atome d'hydrogène ou un groupement acyle ou alkyle, Ar représente un groupement aryle ou hétéroaryle, A représente un groupement choisi parmi: R4 représente un atome d'hydrogène ou un groupement alkyle, R5 représente un atome d'hydrogène ou un groupement choisi parmi alkyle, aryle et hétéroaryle, R3 représente un groupement aryle, hétéroaryle, dicyclopropylméthyle ou benzhydryle, ou A-R3 représente un groupement naphtyle éventuellement substitué, à l'exclusion de la 2,5-dihydroxy-3-(4-méthoxyphényl)-6-(2-phényléthényl)-1,4-benzoquinone, de la 2,5-dihydroxy-3-(4-méthoxyphényl)-6-(2-naphtyl)-1,4-benzoquinone, et de la 2,5-dihydroxy-3-(2-naphtyl)-6-phényl-1,4-benzoquinone. Médicaments.

公开(公告)号：AT277027T

公开(公告)日：2004-10-15

申请号：AT02291501

申请日：2002-06-17

Applicant: SERVIER LAB

Inventor： WIERZBICKI MICHEL ,  FOURQUEZ JEAN-MARIE ,  LEVENS NIGEL ,  HUSSON-ROBERT BERNADETTE ,  NOSJEAN OLIVIER ,  BOULANGER MICHELLE

IPC: C07D295/18 ,  A61K31/16 ,  A61K31/397 ,  A61K31/40 ,  A61K31/403 ,  A61K31/426 ,  A61K31/4453 ,  A61K31/5375 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  C07C237/14 ,  C07D205/04 ,  C07D207/18 ,  C07D207/20 ,  C07D209/02 ,  C07D209/52 ,  C07D277/04 ,  C07D277/22 ,  C07D295/185

Abstract: A compound of formula (I):wherein:represents an optionally substituted saturated carbon ring having from 4 to 8 ring members,R1 and R4, which may be identical or different, each represents hydrogen or acyl,R2 and R3, which may be identical or different, each represents hydrogen or alkyl,R5 and R6, which may be identical or different, each represents hydrogen or alkyl, or R5 and R6 together, with the nitrogen atom carrying them, form an optionally substituted nitrogen-containing heterocycle,stereoisomers thereof, and also addition salts thereof with a pharmaceutically acceptable acid.Medicinal products containing the same which are useful for treatment of glucose intolerance or of disorders associated with hyperglycaemia.

公开(公告)号：NZ520260A

公开(公告)日：2004-05-28

申请号：NZ52026001

申请日：2001-02-01

Applicant: SERVIER LAB

Inventor： RENARD PIERRE ,  LESIEUR DANIEL ,  BLANC-DELMAS ELODIE ,  YOUS SAID ,  DEPREUX PATRICK ,  DACQUET CATHERINE ,  LEVENS NIGEL ,  BOUTIN JEAN ALBERT ,  BENNEJEAN CAROLINE ,  GUILLAUMET GERALD

IPC: A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61P1/00 ,  A61P1/04 ,  A61P1/14 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/00 ,  A61P9/00 ,  A61P9/10 ,  A61P9/14 ,  A61P13/00 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/10 ,  A61P21/00 ,  A61P21/04 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07B61/00 ,  C07D263/58 ,  C07D277/68 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04

Abstract: A compound of formula (I) where: X represents an oxygen or sulphur atom or a CH2 or R'2-CH group (where R'2 together with R2 forms an additional bond). R1 and R2, may be identical or different where each represents a hydrogen atom, a linear or branched C1-6 alkyl moiety, an aryl group, an aryl-(C1-6)alkyl group in which the alkyl moiety may be linear or branched, an aryloxy group, an aryl-(C1-6)alkoxy group, a hydroxy group, an amino group, a linear or branched )1-6)alkylamino group or a dialkylamino group; or R1 and R2 together form an oxo, thioxo or imino group; A represents a (C1-6)alkylene chain in which a CH2 group may be replaced by a hetero atom selected from oxygen and sulphur, by an NRa group (where Ra represents a hydrogen atom or a linear or branched (C1-6)alkyl group, or by a phenylene or napthylene group; B, R3 and R4 are defined as disclosed in the specification. A process for the preparation of compounds derived from formula I. Also, pharmaceutical compositions are disclosed for the treatment of various diseases including hyperglycaemia, dyslipidaemia, intestinal inflammatory disorders, type I diabetes, cancer and dementia as examples.

公开(公告)号：AR033735A1

公开(公告)日：2004-01-07

申请号：ARP020101750

申请日：2002-05-14

Applicant: SERVIER LAB

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  BENOIST ALAIN ,  LEVENS NIGEL ,  NOSJEAN OLIVIER ,  HUSSON-ROBERT BERNADETTE ,  BOULANGER MICHELLE

IPC: C07D295/10 ,  A61K31/40 ,  A61K31/426 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  C07D207/16 ,  C07D277/04 ,  C07D277/06 ,  C07D295/185 ,  C07K5/02 ,  C07D295/18 ,  A61K31/33

Abstract: Compuesto de fórmula (1), en la cual fórmula (2) representa un heterociclo que contiene nitrógeno de 5 miembros; Ak representa una cadena alquileno; X representa un enlace simple o un grupo fenileno; R1 y R2, que pueden ser idénticos o diferentes, cada uno representa un átomo de hidrógeno o un grupo alquilo; R3 representa un grupo alquilo, nitro o ciano, cuando Y es CH-NO2; o nitro y ciano cuando Y representa NR4; Y representa NR4 o CH-NO2; R4 representa un átomo de hidrógeno o un grupo alquilo; sus tautómeros cuando estos existen, sus isómeros ópticos y sales de adición de los mismos con un ácido farmacéuticamente aceptable, con exclusión de los compuestos en los cuales, simultáneamente, fórmula (2) representa un heterociclo que contiene nitrógeno de 5 miembros no sustituido; Ak representa el grupo -(CH2)3-; X representa un enlace simple; Y representa NH y R3 representa el grupo nitro. Medicamentos para la intolerancia de glucosa y trastornos asociados a hiperglucemia.

公开(公告)号：SK5712003A3

公开(公告)日：2003-11-04

申请号：SK5712003

申请日：2001-10-11

Applicant: SERVIER LAB

Inventor： FAUCHERE JEAN-LUC ,  ORTUNO JEAN-CLAUDE ,  LEVENS NIGEL ,  CHAMORRO SUSANA ,  BOUTIN JEAN ALBERT

IPC: C07D249/14 ,  A61K31/4196 ,  A61K31/422 ,  A61K31/428 ,  A61K31/4439 ,  A61K31/4709 ,  A61K31/55 ,  A61P3/00 ,  A61P3/04 ,  A61P3/10 ,  A61P9/12 ,  A61P15/10 ,  A61P25/08 ,  A61P25/20 ,  A61P25/22 ,  A61P25/24 ,  A61P43/00 ,  C07D401/04 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D409/14 ,  C07D413/12 ,  C07D417/04 ,  C07D417/12

Abstract: A compound of formula (I): wherein: R1 and R2 represent hydrogen or a group as defined in the description, R3 represents hydrogen or alkyl, alkenyl, alkynyl, aryl, heteroaryl, cycloalkyl or heterocycloalkyl, R4 represents a group of formula (II): wherein W and B are as defined in the description, R5 represents hydrogen or alkyl, A represents a group selected from -A2-, -A1-A2-, -A2-A1- and -A1-A2-A1-, V is as defined in the description.

公开(公告)号：NZ518948A

公开(公告)日：2003-10-31

申请号：NZ51894802

申请日：2002-05-14

Applicant: SERVIER LAB

Inventor： DE NANTEUIL GUILLAUME ,  PORTEVIN BERNARD ,  BENOIST ALAIN ,  LEVENS NIGEL ,  NOSJEAN OLIVIER ,  HUSSON-ROBERT BERNADETTE ,  BOULANGER MICHELLE

IPC: A61K31/40 ,  A61K31/426 ,  A61P3/04 ,  A61P3/08 ,  A61P3/10 ,  C07D207/16 ,  C07D295/10 ,  C07D277/04 ,  C07D277/06 ,  C07D295/185 ,  C07K5/02 ,  C07D207/06 ,  A61K31/425

Abstract: A compound of formula (I) wherein; NA represents a 5-membered nitrogen containing heterocycle optionally substituted by a cyano group; Ak represents an alkylene chain; X represents a single bond or a phenylene group; R1 and R2 each represent H or alkyl; Y represents NR4 or CH-NO2, where R4 is H or alkyl; R3 represents alkyl, nitro or cyano when Y represents CH-NO2 or cyano or nitro when Y is NR4. Also described are pharmaceutical compositions containing formula (I) and a process for making it.

公开(公告)号：DK1252150T3

公开(公告)日：2003-09-29

申请号：DK01904021

申请日：2001-02-01

Applicant: SERVIER LAB

Inventor： LESIEUR DANIEL ,  BLANC-DELMAS ELODIE ,  YOUS SAID ,  DEPREUX PATRICK ,  GUILLAUMET GERALD ,  DACQUET CATHERINE ,  LEVENS NIGEL ,  BOUTIN JEAN ALBERT ,  BENNEJEAN CAROLINE ,  RENARD PIERRE

IPC: A61K31/423 ,  A61K31/428 ,  A61K31/437 ,  A61K31/4439 ,  A61P1/00 ,  A61P1/04 ,  A61P1/14 ,  A61P1/18 ,  A61P3/04 ,  A61P3/06 ,  A61P3/10 ,  A61P5/00 ,  A61P9/00 ,  A61P9/10 ,  A61P9/14 ,  A61P13/00 ,  A61P13/12 ,  A61P15/00 ,  A61P17/06 ,  A61P19/10 ,  A61P21/00 ,  A61P21/04 ,  A61P25/28 ,  A61P35/00 ,  A61P43/00 ,  C07B61/00 ,  C07D263/58 ,  C07D277/68 ,  C07D417/06 ,  C07D471/04 ,  C07D498/04 ,  A61K31/4353

Abstract: Compounds of formula (I): wherein: X represents an oxygen or a sulphur or CH 2 or R 1 and R 2 represent a hydrogen atom, or a group as defined in the description, A represents an alkylene chain as described in the description, B is as defined in the description, R 3 and R 4 represent a hydrogen atom or a group as defined in the description, D represents an optionally substituted benzene, optionally substituted pyrazine, optionally substituted pyrimidine or optionally substituted pyridazine and medicinal products containing the same which are useful in treating or preventing melatoninergic disorders.